pharma · Knee Osteoarthritis · Hypoplastic Left Heart Syndrome · RGBP
Regeneron Ireland Designated
Regeneron Ireland Designated Activity Company (DAC)
Regeneron Ireland Designated trial registry — 10 ClinicalTrials.gov studies with program phase, status, and indication context.
LA MESA, CA, IE HQ
Public company Type
RGBP · NYSE Ticker
Company details
- Status
- Public
- HQ
- LA MESA, CA, IE
- Programs
- 10
- Drugs
- 62
- Patents
- 8292
Regeneron Ireland Designated clinical trials
Registry index of 10 ClinicalTrials.gov studies linked to Regeneron Ireland Designated programs — each row shows trial ID, program name, phase, status, and indication.
Regeneron Ireland Designated trial registry — 10 ClinicalTrials.gov studies with program phase, status, and indication context.
Recent trial activity
Latest clinical program signals indexed for Regeneron Ireland Designated.
-
Autologous (self) mononuclear cells derived from umbilical cord blood — Phase 2
Clinical update -
Regen Matrix-PRP-XLHA — Unknown
Clinical update -
hyaluronic Acid + platelet-rich plasma — Approved
Clinical update -
Cellular Matrix / A-CP-HA Kit — Approved
Clinical update -
Placebo — Unknown
Clinical update -
Extracellular Vesicles from Mesenchymal Stem Cells — Phase 1
Clinical update -
Autologous mononuclear cells — Phase 1
Clinical update -
autologous cell-based delivery — Phase 1
Clinical update